<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Topotecan and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C) is an effective anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> regimen </plain></SENT>
<SENT sid="2" pm="."><plain>A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: MTA consisted of Mylotarg 9 mg/m(2) intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m(2) over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m(2) by continuous infusion i.v. on days 1 through 5 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A group of 17 patients (9 primary resistant, 8 relapsed) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) received 20 courses of MTA </plain></SENT>
<SENT sid="5" pm="."><plain>The median age of the patients was 55 years (20-70 years) </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients (12%) achieved complete remission </plain></SENT>
<SENT sid="7" pm="."><plain>The median overall survival was 8.2 weeks </plain></SENT>
<SENT sid="8" pm="."><plain>Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">hepatic venoocclusive disease</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: MTA was moderately effective and associated with significant toxicity in patients with refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>